Results 191 to 200 of about 89,290 (238)

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.

Lancet. Infectious Diseases (Print), 2020
BACKGROUND Nosocomial pneumonia due to multidrug-resistant Gram-negative pathogens poses an increasing challenge. We compared the efficacy and safety of cefiderocol versus high-dose, extended-infusion meropenem for adults with nosocomial pneumonia ...
R. Wunderink, Y. Matsunaga, M. Ariyasu, P. Clevenbergh, R. Echols, K. Kaye, M. Kollef, A. Menon, J. Pogue, A. Shorr, J. Timsit, M. Zeitlinger, T. Nagata   +12 more
semanticscholar   +1 more source

Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study.

Clinical Infectious Diseases, 2020
INTRODUCTION This study aims to assess the association of piperacillin/tazobactam and meropenem minimum inhibitory concentration (MIC) and beta-lactam resistance genes with mortality in the MERINO trial.
Andrew Henderson, Andrew Henderson, David L. Paterson, Mark D. Chatfield, P. Tambyah, D. Lye, D. Lye, D. Lye, P. De, R. Lin, K. L. Chew, M. Yin, T. H. Lee, T. H. Lee, T. H. Lee, M. Yılmaz, R. Çakmak, T. Alenazi, Y. Arabi, M. Falcone, Matteo Bassetti, E. Righi, E. Righi, Benjamin A. Rogers, S. Kanj, H. Bhally, J. Iredell, J. Iredell, M. Mendelson, T. Boyles, David Looke, David Looke, Naomi Runnegar, Naomi Runnegar, Spiros Miyakis, Spiros Miyakis, Spiros Miyakis, G. Walls, M. Khamis, A. Zikri, Amy Crowe, P. R. Ingram, P. R. Ingram, N. Daneman, P. Griffin, P. Griffin, P. Griffin, Eugene Athan, Leah W. Roberts, S. Beatson, Anton Y. Peleg, K. Cottrell, M. Bauer, E. Tan, K. Chaw, Graeme R. Nimmo, T. Harris-Brown, Patrick N. A. Harris, Patrick N. A. Harris, P. Newton, Heather Wren, Maryza Graham, T. Korman, Sameera M Aljohani, B. Alalwan, Khizra Sultana, Assunta Sartor, D. Welch, G. Kahlmeter, Merino Trial Investigators   +69 more
semanticscholar   +1 more source

Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.

Lancet. Infectious Diseases (Print), 2019
BACKGROUND Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated with high mortality. We assessed the efficacy and safety of the combination antibacterial drug ceftolozane-tazobactam versus meropenem for treatment of Gram-negative ...
M. Kollef, Martin Novác̆ek, Ülo Kivistik, Á. Réa-Neto, N. Shime, I. Martín-Loeches, J. Timsit, R. Wunderink, C. Bruno, Jennifer A. Huntington, G. Lin, Brian Yu, J. Butterton, Elizabeth G. Rhee   +13 more
semanticscholar   +1 more source

Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.

Lancet. Infectious Diseases (Print)
BACKGROUND There is a need for additional therapeutic options for serious infections caused by Gram-negative pathogens. In the phase 3, descriptive REVISIT study, we investigated the safety and efficacy of aztreonam-avibactam in the treatment of ...
Y. Carmeli, J. M. Cisneros, Mical Paul, George L. Daikos, Minggui Wang, J. Torre-Cisneros, George Singer, Ivan Titov, Illia Gumenchuk, Yongjie Zhao, Rosa M Jimenez-Rodriguez, Lu Liang, Gang Chen, Oleksandr Pyptiuk, Firdevs Aksoy, Halley Rogers, M. Wible, Francis F Arhin, Alison Luckey, Joanne Leaney, Rienk Pypstra, Joseph W Chow   +21 more
semanticscholar   +1 more source

Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy
Phage-antibiotic combination treatment is a novel noteworthy drug delivery method in anti-infection. In the current study, we have isolated a new phage, pB23, against carbapenem-resistant Acinetobacter baumannii 2023.
Jun Luo, Min Liu, Wen Ai, Xiaoling Zheng, Shaowei Liu, Kuo Huang, Changlin Zhang, Qianyuan Li, Chunhua Luo   +8 more
semanticscholar   +1 more source

Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient

Pediatric Pulmonology, 2020
Cystic fibrosis is associated with significant morbidity and early mortality due to recurrent acute and chronic lung infections. The chronic use of multiple antibiotics without pathogen eradication increases the possibility of extensive drug resistance ...
Andrew B. Gainey, A. Burch, M. Brownstein, David E. Brown, J. Fackler, Bri'Anna Horne, B. Biswas, Brittany N. Bivens, Francisco Malagon, Robert Daniels   +9 more
semanticscholar   +1 more source

Meropenem

Reactions Weekly
  +9 more sources

Meropenem

Reactions Weekly, 2023
  +6 more sources